Search results
Prostate Cancer
Verywell Health via Yahoo News· 1 year agoProstate cancer is the most commonly diagnosed cancer in males, with risk factors including advanced age and a family history of the condition....
AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use
Zacks via Yahoo Finance· 2 years agoAstraZeneca AZN and partner Merck MRK announced that the Committee for Medicinal Products for Human...
AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan
Zacks via Yahoo Finance· 9 months agoAstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to...
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
Zacks via Yahoo Finance· 1 year agoThe FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for...
Point radiopharma drug results disappoint in prostate cancer study
BioPharma Dive via Yahoo Finance· 5 months agoDive Brief: A targeted radiation drug being developed by Indianapolis-based Point BioPharma met its...
Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More
Zacks via Yahoo Finance· 1 year agoEli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based...
AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal
Zacks via Yahoo Finance· 1 year agoAstraZeneca AZN announced an agreement to acquire private biotech, Neogene Therapeutics to build its...
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
Zacks via Yahoo Finance· 2 years agoSanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung...
Biden touts next steps on 'Cancer Moonshot' in speech at JFK library
NBC News via Yahoo News· 2 years agoBiden will announce steps to expand on his "Cancer Moonshot" initiative to prevent deaths from the...
J&J to buy targeted cancer therapy developer Ambrx for $2 billion
Reuters via Yahoo Finance· 5 months agoJ&J will pay $28 per share of Ambrx, which represents a premium of about 105% to the stock's last...